Overview

Safety, Tolerability, PK, PD, and Immunogenicity of Single and Multiple Ascending Intravenous Doses of FR104

Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
First-in-human, phase I, randomized, double-blind, placebo-controlled, single center study evaluating single and multiple ascending intravenous doses of FR104 in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
OSE Immunotherapeutics